

IN THE CLAIMS:

Listing of Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently amended) A topical nanoparticulate spironolactone formulation comprising nanoparticles having a mean diameter, measured by photon correlation spectroscopy, in the range of from about 300 nm to about 900 nm, incorporated into a crystalline network system comprising a dispersion of solid crystals of polar lipids, said lipids exposing their hydrophilic side outwards and their hydrophobic side inwards towards toward the spironolactone nanoparticles.
2. (Currently amended) [A] The formulation according to claim 1, comprising nanoparticles having a mean diameter, measured by photon correlation spectroscopy, in the range of from about 400 nm to about 600 nm
3. (Currently amended) [A] The formulation according to ~~claims 1 or 2~~ claim 1, wherein the lipid has a crystallisation crystallization temperature of between 20°C and 100°C.
4. (Currently amended) [A] The formulation according to ~~claims 1 to 3~~ claim 1, wherein the lipid crystals are β crystals of a monoglyceride of a fatty acid having 12-18 carbon atoms, or ascorbic, phosphate or lactic esters of fatty acids or of monoglycerol ethers, or mixtures thereof.
5. (Currently amended) [A] The formulation according to claim 4, wherein the monoglyceride is 1-monolaurin, 1-monomyristin, 1-monopalmitin, or 1-monostearin, or a mixture of two or more thereof of these.

6. (Currently amended) [A] The formulation according to claims 1 to 5 claim 1,
~~wherein the~~ wherein crystalline network structures of polar lipids are formed within a
polar liquid.

7. (Currently amended) [A] The formulation according to any of claim 6, wherein
the polar liquid is selected from ~~the group comprising~~ water, glycerol, ethylene glycol,
[or] propylene glycol, or mixtures thereof.

8. (Currently amended) A method of treating one or more of acne, hirsutism,
androgenic alopecia, or rosacea, comprising topically applying to a subject in need
thereof the topical nanoparticulate spironolactone formulation according to claim 1. any
of claims 1 to 7 for use in the topical treatment of acne, hirsutism, androgenic alopecia
or rosacea.

9. (Currently amended) [A] The formulation according to claims 1 to 8 claim 1,
wherein [the] active drug is incorporated in the form of a nanosuspension.

10. (Currently amended) [A] The formulation according to claim 9, wherein the
nanosuspension is an aqueous nanosuspension.

11. (Currently amended) [A] The formulation according to claim 10, wherein the
nanosuspension comprises a stabiliser stabilizer.

12. (Currently amended) [A] The formulation according to claim 11, wherein the
stabiliser stabilizer is sodium docusate.

13. (Canceled)

14. (Currently amended) [Use] The method according to claim [13] 22, wherein the condition is selected from acne, hirsutism, androgenic alopecia, or rosacea.
15. (Currently amended) [Use] The method according to claims 13 or 14 claim 22, wherein the ~~medicament is adapted for topical application~~ spironolactone nanosuspension is topically applied.
16. (Currently amended) [Use] The method according to claims 13 to 15 claim 22, wherein the nanoparticles are incorporated into a cream base.
17. (Currently amended) [Use] The method according to claim 16, wherein the cream base ~~consists of~~ comprises a crystalline network of monoglycerides in water or other polar liquids.
18. (Currently amended) A method of treating a condition ~~responding that responds~~ to anti-androgens comprising: administering a nanoparticulate spironolactone formulation according to claims 1 to 6 claim 1 to a patient in need of such treatment.
19. (Currently amended) [A] The method according to claim 18, wherein said condition is selected from the group consisting of acne, hirsutism, androgenic alopecia [or] and rosacea.
20. (Currently amended) A crystalline network system comprising a dispersion of solid crystals of polar lipids, said lipids ~~exposing~~ having their hydrophilic side exposed outwards and their hydrophobic side inwards ~~towards~~ toward an incorporated substance, for use in the topical treatment of acne.
21. (Currently amended) A process for the preparation of a topical nanoparticulate spironolactone formulation comprising nanoparticles having a mean diameter in the range of from about 300 nm to about 900 nm as measured by photon correlation

spectroscopy, ~~in the range of from 300nm to about 900nm, wherein the said process comprises comprising: incorporating incorporation of~~ a nanosuspension of spironolactone into an aqueous dispersion of solid crystals of polar lipids, said lipids ~~exposing having their hydrophilic side exposed~~ outwards and their hydrophobic side inwards ~~towards toward~~ the spironolactone nanoparticles.

22. (New) A method of treating a condition that responds to anti-androgens, comprising: administering a spironolactone nanosuspension comprising nanoparticles having a mean diameter in the range of from about 300 nm to about 900 nm, as measured by photon correlation spectroscopy, in an amount effective to treat the condition.
23. (New) The method according to claim 8, wherein spironolactone active drug is incorporated into the formulation in the form of a nanosuspension.
24. (New) The method according to claim 18, wherein spironolactone active drug is incorporated into the formulation in the form of a nanosuspension.